Radiopharm 6-K on key opinion leader webinars

Radiopharm Theranostics Limited furnished a Form 6-K to the U.S. Securities and Exchange Commission to share information previously announced on the Australian Securities Exchange.

Accepted by SEC EDGAR 08/21/2025 - 07:20 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Radiopharm Theranostics Limited furnished a Form 6-K to the U.S. Securities and Exchange Commission to share information previously announced on the Australian Securities Exchange. The filing attaches an announcement titled “Radiopharm to host key opinion leader webinar series” as an exhibit.

The company states that this Form 6-K and its exhibit are being furnished, not filed, under U.S. securities laws, meaning they are not automatically incorporated into other U.S. securities law filings unless specifically referenced.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Radiopharm Theranostics (RADX) disclose in this Form 6-K?

Radiopharm Theranostics discloses that it furnished to the SEC an announcement previously released on the Australian Securities Exchange titled “Radiopharm to host key opinion leader webinar series.” This announcement is attached as Exhibit 99.1 to the Form 6-K.

What is Exhibit 99.1 in Radiopharm Theranostics’ (RADX) August 2025 Form 6-K?

Exhibit 99.1 is an announcement titled “Radiopharm to host key opinion leader webinar series.” The Form 6-K simply furnishes this Australian Securities Exchange announcement to U.S. investors without adding financial results or transaction details.

Is the Radiopharm Theranostics (RADX) Form 6-K considered filed or furnished?

The Form 6-K is expressly described as being furnished, not filed, under the U.S. Exchange Act. As a result, it is not automatically incorporated into other U.S. securities filings unless explicitly referenced in those future documents.

Does the Radiopharm Theranostics (RADX) Form 6-K include the full key opinion leader webinar details?

The Form 6-K itself does not describe the webinar series in detail. Instead, it attaches the Australian Securities Exchange announcement titled “Radiopharm to host key opinion leader webinar series” as Exhibit 99.1, where those details are expected to appear.

Who signed the Radiopharm Theranostics (RADX) Form 6-K and when?

The Form 6-K was signed on behalf of Radiopharm Theranostics Limited by Phillip Hains, identified as Company Secretary. The signature block is dated August 21, 2025, matching the date of the related Australian Securities Exchange announcement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of August 2025

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐       No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on August 21, 2025 titled:

- “Radiopharm to host key opinion leader webinar series”

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

1

EXHIBITS

Exhibit Number		Description
99.1		Radiopharm to host key opinion leader webinar series

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED
Date: August 21, 2025	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

3